Adaptive TCR Raises $5.8M to Invest in Clinical Applications
June 15, 2011
Adaptive TCR Raises $5.8M to Invest in Clinical Applications
The latest investment will be used to grow the company's immune system sequencing service, immunoSeq, and "invest in clinical applications in the oncology, autoimmune, and vaccine fields," CEO Chad Robins said in a statement.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Adaptive Biotech Targets Year End for CLIA Certification, Assay to Detect Residual Leukemia
May 23, 2012 / Clinical Sequencing News - HudsonAlpha Researchers to Sequence Immune Repertoires of 10K Individuals for 100 Diseases
May 24, 2011 / Clinical Sequencing News - Immune Sequencing Project Will Test Technology's Ability to Diagnose Pathogen Exposure
April 12, 2011 / Clinical Sequencing News - Adaptive Bio, Bristol-Myers Squibb Collaborate on Cancer Biomarkers
May 9, 2013 / GenomeWeb Daily News - Adaptive TCR Changes Name to Adaptive Biotechnologies
January 4, 2012 / Clinical Sequencing News